前列腺癌診斷市場規模、佔有率和成長分析（按檢測類型、技術、癌症類型、最終用戶、應用和地區分類）：產業預測（2026-2033 年）

2024 年全球攝護腺癌診斷市場價值為 91 億美元，預計到 2033 年將成長至 160.4 億美元，而 2025 年為 96.9 億美元，預測期（2026-2033 年）的複合年成長率為 6.5%。

全球前列腺癌診斷市場受到前列腺癌發生率不斷上升、篩檢項目不斷改進以及技術創新顯著影響。該市場涵蓋多種工具，包括利用分子分型方法進行精準疾病檢測和表徵的生化檢測、影像學技術和切片檢查系統。從廣泛的PSA篩檢轉向更具針對性的方法，例如多參數磁振造影和基因組檢測，正在推動對非侵入性診斷工具的投資。臨床效用的提升，以及強而有力的實證醫學證據和完善的醫保報銷機制，正在加速這些創新技術的應用和普及。一個顯著的趨勢是用更有效的方法取代傳統的影像學技術，從而提高風險分層和營運效率。因此，在診斷需求尚未滿足的新興地區和綜合醫療服務體系中，商機正不斷擴大。

全球前列腺癌診斷市場成長要素

全球前列腺癌診斷市場正受到分子診斷技術進步的顯著推動。分子診斷技術具有更高的特異性，能夠更深入地了解前列腺癌的生物學特徵。這種準確性的提升使臨床醫生在做出診斷決策時更有信心，並有助於制定個人化的治療方案。隨著越來越多的醫療專業人員和患者認知到分子檢測的益處，對能夠區分高侵襲性和低進展性前列腺癌的檢測方法的需求日益成長。為此，檢測實驗室和診斷公司正在擴展其產品線，並將分子檢測納入標準臨床實務。這一趨勢不僅推動了市場成長，也促進了對相關技術和創新商業性模式的投資。

全球前列腺癌診斷市場面臨的限制因素

全球前列腺癌診斷市場面臨許多挑戰，其中最主要的原因是各地區監管要求的複雜性和多樣性，阻礙了新型診斷測試的快速商業化。全面的臨床檢驗和詳盡的文件記錄往往導致市場准入延遲和初期研發成本上升。製造商在不同地區面臨不同的證據標準和核准流程，延緩了創新技術惠及臨床醫師和病患的速度。這種監管上的不確定性阻礙了投資和策略成長，迫使企業將目光轉向流程更為簡單的市場，最終限制了先進診斷技術在全球的應用。

全球前列腺癌診斷市場趨勢

全球前列腺癌診斷市場正呈現出非侵入性診斷方法日益普及的趨勢，這反映了臨床醫生和患者對便利性和舒適性的日益成長的偏好。創新的血液和尿液生物標記檢測，與先進的影像技術相輔相成，正擴大被整合到患者照護階段，以增強風險分層並減少對侵入性檢查的依賴。為此，診斷設備製造商正積極研發兼顧臨床效用和病患依從性的產品，同時確保其在各種醫療環境中的便利部署。這一趨勢正推動非侵入性診斷在基層和專科醫療網路中的廣泛應用，從而形成可擴充性的解決方案，以改善患者的治療效果。

目錄

介紹

• 分析目的
• 市場定義和範圍

分析方法

• 分析過程
• 二級資料和一級資料的方法
• 估算市場規模的方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態與展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特五力分析及其影響

關鍵市場觀察

• 主要成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 市場魅力指數（2025）
• PESTLE分析
• 監理情勢
• 價值鏈分析
• 案例研究
• 技術評估
• 客戶和採購標準分析
• 管道分析
• 疾病流行病學

全球前列腺癌診斷市場規模：按檢測類型分類

• 初步檢查
• 確認性試驗
• PSA檢測
• 免費PSA檢測
• 總PSA檢測
• PCA3 測試
• 切片檢查
• 影像檢查

全球前列腺癌診斷市場規模：依技術分類

• 分子診斷
• 免疫測量
• 次世代定序（NGS）
• 基於PCR的檢測
• 人工智慧影像診斷
• 液態生物檢體

全球前列腺癌診斷市場規模：按癌症類型分類

• 腺癌
• 小細胞癌
• 移行細胞癌
• 其他罕見的前列腺癌類型

全球前列腺癌診斷市場規模：按最終用戶分類

• 醫院
• 診斷檢查室
• 癌症研究機構
• 專科診所
• 門診部
• 其他

全球前列腺癌診斷市場規模：按應用領域分類

• 篩檢
• 風險評估
• 早期檢測
• 腫瘤分期
• 後續觀察和復發檢測
• 其他

全球前列腺癌診斷市場規模：按地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭格局

• 前五大公司對比
• 主要公司的市場定位（2025 年）
• 主要公司採取的策略
• 近期市場趨勢
• 主要公司市佔率（2025 年）
• 主要公司簡介
  • 公司簡介
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 2023-2025年營收年比比較

主要公司簡介

• F. Hoffmann-La Roche Ltd
• Abbott Laboratories
• Siemens Healthineers AG
• Danaher Corporation
• Thermo Fisher Scientific Inc.
• Bio-Rad Laboratories, Inc.
• QIAGEN NV
• Myriad Genetics, Inc.
• MDxHealth SA
• Exact Sciences Corporation
• OPKO Health, Inc.
• Hologic, Inc.
• Becton, Dickinson and Company
• Agilent Technologies, Inc.
• Illumina, Inc.
• GE HealthCare Technologies Inc.
• Koninklijke Philips NV
• Sysmex Corporation
• DiaSorin SpA
• Beckman Coulter, Inc.

結論與建議

Global Prostate Cancer Diagnostics Market size was valued at USD 9.1 Billion in 2024 and is poised to grow from USD 9.69 Billion in 2025 to USD 16.04 Billion by 2033, growing at a CAGR of 6.5% during the forecast period (2026-2033).

The global prostate cancer diagnostics market is significantly influenced by the increasing prevalence of prostate cancer, alongside advancements in screening programs and technological innovations. This market encompasses a variety of tools, including biochemical assays, imaging techniques, and biopsy systems that utilize molecular classifiers for precise disease detection and characterization. The transition from broad PSA screening to targeted approaches, such as multiparametric MRI and genomic testing, has prompted investments in noninvasive diagnostic tools. Enhanced clinical utility, supported by substantial evidence and reimbursement frameworks, is fostering adoption and scaling of these innovations. Notable trends include the replacement of traditional imaging methods with more effective technologies, leading to improved risk stratification and operational efficiencies. Consequently, opportunities are growing in integrated care pathways and in emerging regions with unmet diagnostic needs.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Prostate Cancer Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Prostate Cancer Diagnostics Market Segments Analysis

Global prostate cancer diagnostics market is segmented by test type, technology, cancer type, end user, application and region. Based on test type, the market is segmented into preliminary tests, confirmatory tests, PSA tests, free PSA tests, total PSA tests, PCA3 tests, biopsy tests and imaging tests. Based on technology, the market is segmented into molecular diagnostics, immunoassays, next-generation sequencing (NGS), PCR-based testing, AI-based imaging diagnostics and liquid biopsy. Based on cancer type, the market is segmented into adenocarcinoma, small cell carcinoma, transitional cell carcinoma and other rare prostate cancer types. Based on end user, the market is segmented into hospitals, diagnostic laboratories, cancer research institutes, specialty clinics, outpatient facilities and others. Based on application, the market is segmented into screening, risk assessment, early detection, tumor staging, monitoring & recurrence detection and others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Prostate Cancer Diagnostics Market

The Global Prostate Cancer Diagnostics market is significantly driven by the advancements in molecular diagnostics, which provide greater specificity and improved characterization of prostate cancer biology. This enhanced accuracy bolsters clinicians' confidence in making diagnostic decisions and facilitates personalized treatment strategies. As more healthcare providers and patients recognize the benefits of molecular testing, the demand for assays that differentiate between aggressive and indolent prostate cancer intensifies. In response, laboratories and diagnostic firms are expanding their product offerings and incorporating molecular assays into standard clinical practices. This trend not only supports market growth but also attracts investments in complementary technologies and innovative commercial approaches.

Restraints in the Global Prostate Cancer Diagnostics Market

The Global Prostate Cancer Diagnostics market faces challenges due to the complex and varied regulatory requirements in different regions, which hinder the swift commercialization of new diagnostic tests. The necessity for comprehensive clinical validation and thorough documentation often leads to delays in market entry and amplifies initial development costs. Manufacturers encounter diverse evidentiary standards and approval processes, slowing the delivery of innovations to clinicians and patients. This regulatory ambiguity can deter investment and strategic growth, prompting companies to focus on markets with more straightforward procedures, ultimately restricting the wider global adoption of advanced diagnostic technologies.

Market Trends of the Global Prostate Cancer Diagnostics Market

The Global Prostate Cancer Diagnostics market is witnessing a notable trend toward the adoption of noninvasive testing methods, reflecting a shift in clinician and patient preferences for convenience and comfort. Innovative blood and urine biomarker assays, complemented by advanced imaging techniques, are increasingly integrated earlier in patient care pathways to enhance risk stratification and reduce the reliance on invasive procedures. In response, diagnostic companies are strategically developing products that emphasize clinical utility and patient adherence while ensuring ease of implementation in various healthcare settings. This trend is fostering the expansion of noninvasive diagnostics across primary and specialty care networks, enabling scalable solutions for improved patient outcomes.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Value Chain Analysis
• Case Studies
• Technology Assessment
• Customer & Buying Criteria Analysis
• Pipeline Analysis
• Disease Epidemiology

Global Prostate Cancer Diagnostics Market Size by Test Type & CAGR (2026-2033)

• Market Overview
• Preliminary Tests
• Confirmatory Tests
• PSA Tests
• Free PSA Tests
• Total PSA Tests
• PCA3 Tests
• Biopsy Tests
• Imaging Tests

Global Prostate Cancer Diagnostics Market Size by Technology & CAGR (2026-2033)

• Market Overview
• Molecular Diagnostics
• Immunoassays
• Next-generation Sequencing (NGS)
• PCR-based Testing
• AI-based Imaging Diagnostics
• Liquid Biopsy

Global Prostate Cancer Diagnostics Market Size by Cancer Type & CAGR (2026-2033)

• Market Overview
• Adenocarcinoma
• Small Cell Carcinoma
• Transitional Cell Carcinoma
• Other Rare Prostate Cancer Types

Global Prostate Cancer Diagnostics Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Diagnostic Laboratories
• Cancer Research Institutes
• Specialty Clinics
• Outpatient Facilities
• Others

Global Prostate Cancer Diagnostics Market Size by Application & CAGR (2026-2033)

• Market Overview
• Screening
• Risk Assessment
• Early Detection
• Tumor Staging
• Monitoring & Recurrence Detection
• Others

Global Prostate Cancer Diagnostics Market Size & CAGR (2026-2033)

• North America (Test Type, Technology, Cancer Type, End User, Application)
  • US
  • Canada
• Europe (Test Type, Technology, Cancer Type, End User, Application)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Test Type, Technology, Cancer Type, End User, Application)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Test Type, Technology, Cancer Type, End User, Application)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Test Type, Technology, Cancer Type, End User, Application)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• F. Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Siemens Healthineers AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Danaher Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Myriad Genetics, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• MDxHealth SA
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Exact Sciences Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• OPKO Health, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Agilent Technologies, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Illumina, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GE HealthCare Technologies Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Koninklijke Philips N.V.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sysmex Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin S.p.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Beckman Coulter, Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations